CurrentUnitedHealthcarePolicy CS054.W

Airway Clearance Devices

Defines medical necessity and coverage criteria for high-frequency chest wall oscillation (HFCWO) systems and states noncoverage for combination OLE devices and intrapulmonary percussive ventilation (IPV) for home use; includes applicable HCPCS and ICD-10 codes and requirement for an initial 2-month rental trial and InterQual criteria for ongoing use. Excludes certain state-specific applicability.

Policy Summary

PayerUnitedHealthcare

PolicyAirway Clearance Devices

Policy CodePolicy CS054.W

Change TypeRevised clinical criteria & documentation requirements

Effective DateMar 1, 2026

Next Review Date

Key ActionObtain an initial 2-month rental trial and provide required medical record documentation (device requested and trial status, recent imaging/diagnostics, comorbidities, treatments tried/failed with dates/duration/reason, and evidence of proper use for continuation) to support coverage.

SourceLink

POLICY UPDATE CHANGES

Updated medical necessity clinical coverage criteria for high-frequency chest wall oscillation (HFCWO) system and replaced an InterQual reference.

Updated list of medical records documentation used for reviews with added required items and removed some prior items.

Removed content/language pertaining to the state of Louisiana.

Updated supporting information (Description of Services, Clinical Evidence, References) to reflect current information.

3Covered Indications (HFCWO)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Scope: Defines medical necessity and coverage criteria for high-frequency chest wall oscillation (HFCWO) systems, including an initial 2-month rental trial to confirm individual tolerance and efficacy, the covered indications (neuromuscular diseases, bronchiectasis, and cystic fibrosis), applicable HCPCS/ICD-10 codes, and reliance on InterQual® criteria for ongoing coverage decisions; explicitly states that combination OLE devices and IPV for home use are considered unproven and not medically necessary.

Policy-level summary

Effective dateMarch 1, 2026

Policy numberCS054.W

Typical trial periodInitial 2-month rental trial (2-month)

Coverage stance summaryCovered (proven and medically necessary) for HFCWO in neuromuscular diseases, bronchiectasis, and cystic fibrosis when criteria met; HFCWO unproven for other conditions; OLE and IPV for home use considered unproven and not medically necessary. Refer to InterQual® criteria for ongoing coverage.

Medical-Necessity Criteria

Medically Necessary - HFCWO 2-month rental trial

Covered when ALL of the following are met:

ALL of the following

Initial 2-month rental trial of a high-frequency chest wall oscillation (HFCWO) system is performed to confirm individual tolerance and efficacy
See ICD-10 code list for included diagnoses
Indication is one of: neuromuscular diseases, Bronchiectasis, or cystic fibrosis
For ongoing medical necessity after trial, member meets InterQual® Client Defined, CP: Durable Medical Equipment, Airway or Secretion Clearance Devices (Custom) - UHG criteria
Refer to InterQual® criteria (link referenced)

Documentation and Medical Records Requirements (as updated 03/01/2026)

Medical records documentation used for reviews must include the following:

Not Medically Necessary / Unproven

Not covered when ANY of the following apply:

ANY of the following

Use of HFCWO for any condition other than neuromuscular diseases, Bronchiectasis, or cystic fibrosis
Insufficient evidence of efficacy
Combination continuous positive expiratory pressure, continuous high-frequency oscillation, and nebulized medication therapy devices for oscillation and lung expansion (OLE)
Considered unproven and not medically necessary
Intrapulmonary percussive ventilation (IPV) devices for home use
Considered unproven and not medically necessary

Provider Actions & Prior Authorization

Prior Authorization

Initial rental trial and ongoing medical necessity assessment

An initial 2-month rental trial is required to confirm individual tolerance and efficacy of an HFCWO system. Ongoing coverage beyond the trial requires documentation demonstrating medical necessity per InterQual® (Client Defined, CP: Durable Medical Equipment, Airway or Secretion Clearance Devices - UHG).

Affected codes: E0483, E0469, A7021

Prior Authorization

Trial period and continuation documentation

Continuation of device rental or purchase beyond the initial 2-month trial requires submission of documentation showing proper device use during the trial and evidence of clinical benefit. Coverage determinations reference InterQual® criteria for ongoing medical necessity.

Submit evidence of benefit during the 2-month trial (e.g., symptom improvement, sputum clearance, reduced exacerbations, objective measures)

Coding

DME / HCPCS codes referencedHCPCS

A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter)
A7025	High frequency chest wall oscillation system vest, replacement for use with patient-owned equipment, each
A7026	High frequency chest wall oscillation system hose, replacement for use with patient-owned equipment, each
E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device
E0481	Intrapulmonary percussive ventilation system and related accessories
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each

Applicable ICD-10 diagnoses (covered indications list)ICD-10

A80.0	Acute paralytic poliomyelitis, vaccine-associated
A80.1	Acute paralytic poliomyelitis, wild virus, imported
A80.2	Acute paralytic poliomyelitis, wild virus, indigenous
A80.30	Acute paralytic poliomyelitis, unspecified
A80.39	Other acute paralytic poliomyelitis
A80.4	Acute nonparalytic poliomyelitis
A80.9	Acute poliomyelitis, unspecified
B91	Sequelae of poliomyelitis
E74.02	Pompe disease
E74.4	Disorders of pyruvate metabolism and gluconeogenesis

1–10 of 62

1/7

Regulatory / informational product code referencedmixed

BYI	FDA product code referenced for HFCWO devices (informational)

Clinical Evidence & Background

This policy covers the physiology and clinical rationale for airway clearance when cough and ciliary action are insufficient, describes device mechanisms (HFCWO = external inflatable vest producing rapid chest wall oscillations to mobilize mucus; IPV = intrapulmonary percussive ventilation delivering mini-bursts via a mouthpiece; OLE = combination continuous PEP + continuous HFCWO with nebulized medications), and summarizes the evidence context: multiple systematic reviews, RCTs, cohort and registry studies show support for HFCWO in cystic fibrosis, bronchiectasis, and neuromuscular disease but with variable quality of evidence and need for further well-designed RCTs; by contrast, the evidence for OLE and IPV—particularly for routine long-term home use—is insufficient or heterogeneous, and these are considered unproven and not medically necessary for home use.

Clinical Evidence Summary — Findings influencing coverage decisions

Evidence and guideline conclusions summarized (each bullet reflects study/review conclusions that inform coverage stance).

Systematic reviews on ACT equivalence: Systematic reviews (e.g., Cochrane/Main 2023, Morrison & Milroy 2020) found very low- to low-certainty evidence that CCPT, HFCWO, IPV, O-PEP, and other ACTs are generally equivalent for lung function and exacerbation outcomes in cystic fibrosis and bronchiectasis.

No superiority and possible increased exacerbations:

Definitions

Term	Definition
Bronchiectasis	A chronic respiratory disease associated with dilation of the airways and recurrent or chronic infections; clinically significant bronchiectasis has at least two of: cough most days, sputum production most days, or history of exacerbations; confirmed by CT scan.
HFCWO	High-frequency chest wall oscillation device used to promote airway clearance by external chest wall oscillations.
IPV	Intrapulmonary percussive ventilation: percussive breaths delivered via a device to mobilize secretions.
OLE	Oscillation and lung expansion combination therapy (e.g., continuous high-frequency oscillation + continuous PEP).
CCPT	Conventional chest physiotherapy (manual techniques).

Revision History

03/01/2026revisedLatest

Updated medical necessity clinical coverage criteria for high-frequency chest wall oscillation (HFCWO) system and replaced an InterQual reference; detail: Replaced 'InterQual ® Client Defined, CP: Durable Medical Equipment, Secretion Clearance Devices (Custom) - UHG' with 'InterQual ® Client Defined, CP: Durable Medical Equipment, Airway or Secretion Clearance Devices (Custom) - UHG'.

03/01/2026revised

Updated list of medical records documentation used for reviews with added required items and removed some prior items; detail: Added specific device request status, imaging results, comorbidities, and requirement for proper use documentation for continuation; removed requirement for current physician prescription and CT scan report confirming bronchiectasis; changed phrasing on failed treatments to require dates/duration/reason for discontinuation.

Study / Source	Key finding
Evidence summary	Multiple systematic reviews, RCTs, cohort and registry studies show benefits of HFCWO for sputum expectoration, reduced hospitalizations, and improved patient-reported outcomes in CF, bronchiectasis, and neuromuscular disease, but overall evidence quality and consistency varies; other devices lack sufficient evidence.
Cochrane/Main (2023) on CCPT vs alternative ACTs	Very low-certainty evidence; generally no difference in FEV1/FVC changes; unable to recommend a single ACT above others.
Morrison & Milroy (2020)	No clear evidence oscillation devices are more effective than other ACTs; evidence low/very low quality.
Huynh et al. (2019)	OLE treatment reduced postoperative pulmonary complications from 22.9% to 15.8% and reduced ventilator time and hospital LOS in a nonrandomized prospective study; authors call for RCTs.
Hassan et al. (2024 RCT)	IPV reduced ICU length of stay and improved oxygenation modestly vs conventional physiotherapy in critically ill nonventilated patients (single-center RCT).
Nicolini et al. (2018 RCT)	IPV and HFCWO showed improvements vs control in COPD over 4 weeks; IPV had some superior secondary outcomes; small single-center trial.
Lechtzin et al. (2016) / Barto et al. (2020) registry/cohort	Real-world data/registry analyses showed reduced hospitalizations and antibiotic use and improved patient-reported airway clearance after initiating HFCWO in bronchiectasis and neuromuscular disease cohorts; nonrandomized designs limit causality.
González-Bellido et al. (2021) / Leemans et al. (2020) / Fitzgerald et al. (2014)	RCTs and pilot studies indicate HFCWO is generally safe and can provide comparable sputum clearance to other devices in short-term or small studies; evidence limited by small size and heterogeneity.